There is no foolproof way to know the future Gilead Sciences (Nasdaq: GILD) or any other company. However, some clues may help you see the potential stumbled before they happen--and before that your stock craters accordingly. Rest assured: even if you're monitoring these metrics, short-sellers are.
A cloudy crystal ball
I often use credits (AR) and days sales outstanding (DSO) to judge a company's current health and future prospects. Is an important step to separate the pretenders from the best stocks in the market. Alone, AR--the amount of money towards society--and DSO--days worth of sales due to the company--don't say much. However, taking into account trends in HR and DSO, you can sometimes get a window on the future.
Sometimes, problems with AR or DSO simply indicate a change in the business (as an acquisition), or collections lax. However, AR that grows faster than revenue, DSO or balloon can also suggest a company desperately trying to increase sales by offering its customers the overly generous payment terms. Alternatively, it may indicate that the company sprinted to book a load of sales at the end of the quarter, as used car dealers on the 29th of the month. (Sometimes, the companies do both.)
Because a company loyal as Gilead Sciences could do this? For the same reason than any other company would be: why the numbers. Investors don't like revenue, and employees do not like their reporting to their superiors.
Gilead Sciences is the sending of any potential warning signs? Take a look at the chart below, which pitches revenue growth against DSO and growth of AR:
Source: Capital IQ, a division of Standard & Poor. Data is current as of the last fiscal quarter reported completely. FQ = fiscal quarter.
The standard way to calculate DSO uses average accounts receivable. I prefer to look at the end of quarter (EOQ) credits, but I have both paths above.
Watching trends
When the red line (growth AR) crosses above the green line (growth of revenue), I know that I need to see the iron filings. Similarly, a peak in the blue bars (DSO) indicates a trend worth worrying about. As another control of reality, it is reasonable to consider what might look like a normal figure DSO in this space.
Differences in business models can generate variations in DSO, so don't take into account this word final--just a way to add some context to the numbers. But back to our original question: is Gilead Sciences lose its numbers in the next quarter or two?
Numbers don't paint a clear picture. For the last fiscal quarter reported fully, year-over-year revenue of Gilead Sciences has reduced by 1.7% and its AR grew by 16.7%. That is a yellow flag. End of quarter DSO increased 18.7% over the previous year's quarter. Was down 5.9% from the prior quarter. That requires a good explanation. Still, not the fortuneteller, and these are just numbers. Investors to put their money on the line always need to dig the iron filings to the root causes and draw their own conclusions.
What now?
Use this type of analysis to figure out what investments, I need to look more closely at how hunting yields the best on the market. However, some investors actively companies on the wrong side of HR trends in order to sell their profit when they fall short, in the end. How would play this one? Let us know in the comments below or keep up with the stocks mentioned in this article, take them in our service free watchlist, My Watchlist.
No comments:
Post a Comment